Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells
- PMID: 19399413
- DOI: 10.1007/s11596-009-0221-2
Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells
Abstract
In order to investigate the effect of chitosan/pshRNA plasmid nanoparticles targeting MDR1 genes on the resistance of A2780/TS cells to paclitaxel, chitosan/pshRNA plasmid nanoparticles were synthesized by means of a complex coacervation technique and transfected into A2780/TS cells. The cells transfected with MDR1-targeted chitosan/pshRNA plasmid nanoparticles were experimental cells and the cells transfected with chitosan/pGPU6/GFP/Neo no-load plasmid nanoparticles served as negative control cells. Morphological features of the nanoparticles were observed under transmission electron microscope (TEM). MDR1 mRNA expression was assessed by RT-PCR. Half-inhibitory concentration (IC50) of paclitaxel for A2780/TS cells was determined by MTT method. TEM showed that the nanoparticles were round-shaped, smooth in surface and the diameters varied from 80 to 120 nm. The MDR1 mRNA in the transfected cells was significantly decreased by 17.6%, 27.8% and 52.6% on the post-transfection day 2, 4 and 7 when compared with that in A2780/TS cells control (P<0.05). MTT assay revealed that the relative reversal efficiency was increased over time and was 29.6%, 51.2% and 61.3% respectively in the transfected cells 2, 4, 7 days after transfection and IC50 (0.197+/-0.003, 0.144+/-0.001, 0.120+/-0.004) were decreased with difference being significant when compared with that in A2780/TS (0.269+/-0.003) cells control (P<0.05). It was concluded that chitosan/pshRNA plasmid nanoparticles targeting MDR1 can effectively reverse the paclitaxel resistance in A2780/TS cells in a time-dependent manner.
Similar articles
-
Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo.J Huazhong Univ Sci Technolog Med Sci. 2009 Oct;29(5):620-4. doi: 10.1007/s11596-009-0517-2. Epub 2009 Oct 11. J Huazhong Univ Sci Technolog Med Sci. 2009. PMID: 19821097
-
MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):721-4. doi: 10.1007/s11596-007-0627-7. J Huazhong Univ Sci Technolog Med Sci. 2007. PMID: 18231753
-
[Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel].Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6. Zhonghua Fu Chan Ke Za Zhi. 2007. PMID: 17697605 Chinese.
-
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.Mol Cancer Ther. 2004 Jul;3(7):833-8. Mol Cancer Ther. 2004. PMID: 15252144
-
[Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):96-100. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17645840 Chinese.
Cited by
-
Evaluation of Chitosan-Tripolyphosphate Nanoparticles as a p-shRNA Delivery Vector: Formulation, Optimization and Cellular Uptake Study.J Nanopharm Drug Deliv. 2013 Sep;1(3):266-278. doi: 10.1166/jnd.2013.1027. Epub 2013 Sep 1. J Nanopharm Drug Deliv. 2013. PMID: 26989641 Free PMC article.
-
Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo.J Huazhong Univ Sci Technolog Med Sci. 2009 Oct;29(5):620-4. doi: 10.1007/s11596-009-0517-2. Epub 2009 Oct 11. J Huazhong Univ Sci Technolog Med Sci. 2009. PMID: 19821097
-
Dendritic cell engineering for selective targeting of female reproductive tract cancers.Indian J Med Res. 2018 Dec;148(Suppl):S50-S63. doi: 10.4103/ijmr.IJMR_224_18. Indian J Med Res. 2018. PMID: 30964081 Free PMC article. Review.
-
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.J Oncol. 2012;2012:737981. doi: 10.1155/2012/737981. Epub 2012 Feb 6. J Oncol. 2012. PMID: 22481932 Free PMC article.
-
Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Curr Pharm Des. 2016;22(28):4360-4373. doi: 10.2174/1381612822666160617112111. Curr Pharm Des. 2016. PMID: 27319945 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical